De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population

2001 ◽  
Vol 7 (1) ◽  
pp. 51-58 ◽  
Author(s):  
M Prieto
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
De Novo ◽  
High Prevalence ◽  
Donor Population ◽  
De Novo Hepatitis B

scholarly journals Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 92
Author(s):  
Palittiya Sintusek ◽  
Supranee Buranapraditkun ◽  
Piyaporn Wanawongsawad ◽  
Nawarat Posuwan ◽  
Pattarawat Thantiworasit ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
De Novo ◽  
Controlled Trial ◽  
Geometric Mean ◽  
Interferon Γ ◽  
Specific Response ◽  
Open Label ◽  
High Prevalence ◽  
Randomised Controlled

A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised.

De Novo Hepatitis B and C Viral Infection after Liver Transplantation

1997 ◽  
Vol 21 (1) ◽  
pp. 78-85 ◽  
Author(s):  
Antonino Cavallari ◽  
Emilio De Raffele ◽  
Roberto Bellusci ◽  
Rita Miniero ◽  
Marco Vivarelli ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Viral Infection ◽  
De Novo ◽  
De Novo Hepatitis B

scholarly journals Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 59B-63B ◽  
Author(s):  
Edith Villeneuve ◽  
Jean Vincelette ◽  
Jean-Pierre Villeneuve
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
De Novo ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
De Novo Hepatitis B ◽  
Cirrhotic Patients

Cirrhotic patients who undergo liver transplantation are at risk of acquiring de novo hepatitis B virus (HBV) infection at the time of transplantation. It is common practice to immunize these patients against HBV, but the efficacy of vaccination is uncertain. The response to vaccination with a recombinant HBV vaccine was examined in 49 patients with cirrhosis before liver transplantation. Patients received three doses (20 µg) of Engerix-B (SmithKline Beecham) at zero, one and two months before transplantation, and their response was measured on the day of liver transplantation (9.3±1.2 months after the initial dose of vaccine). Results were compared with those reported in healthy adults vaccinated according to the same schedule. Fourteen of 49 cirrhotic patients (28%) developed antibodies to hepatitis B surface antigen (anti-HBs) levels of more than 10 U/L after vaccination compared with 97% of healthy controls. Four patients (8%) had anti-HBs levels of more than 100 U/L compared with 83% in healthy individuals. Mean anti-HBs titre in the 14 responders was 62 U/L compared with 348 U/L in controls. No factor was identified that predicted response to vaccination. One of 49 patients acquired de novo HBV infection at the time of liver transplantation. Current HBV vaccination of cirrhotic patients waiting for liver transplantation is ineffective, and new strategies need to be developed to increase the response rate.

Sign in / Sign up

Export Citation Format

Share Document